Pro-Urokinase for Myocardial Infarction - PRIMI

Description:

PRIMI was an open-label, prospective pilot trial to determine the effect of simultaneous infusions of low-dose recombinant tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA, pro-urokinase) on coronary arterial thrombolysis in patients with acute myocardial infarction.